Compare SUNS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | RNTX |
|---|---|---|
| Founded | 2023 | 2001 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7M | 89.0M |
| IPO Year | N/A | N/A |
| Metric | SUNS | RNTX |
|---|---|---|
| Price | $8.44 | $0.87 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.75 | ★ $10.00 |
| AVG Volume (30 Days) | 137.4K | ★ 579.2K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 16.17% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.34 | $0.85 |
| 52 Week High | $11.78 | $2.18 |
| Indicator | SUNS | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 39.49 |
| Support Level | $7.39 | $0.85 |
| Resistance Level | $8.86 | $1.05 |
| Average True Range (ATR) | 0.28 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 57.40 | 4.34 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.